<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="antioxidants-09-01260-t003" orientation="portrait" position="float">
 <object-id pub-id-type="pii">antioxidants-09-01260-t003_Table 3</object-id>
 <label>Table 3</label>
 <caption>
  <p>Main studies in relation to thymoquinone (TQ) and 
   <italic>Nigella sativa</italic> (NS) of interest in periodontal disease.
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Type</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Studied, n</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adminitration (Dosage, Frecuency and Duration)</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Effects</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic healthy periodontitis male and female patients with at least 2 periodontally involved sites (≥5 mm), n = 20</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2% TQ topical (intra-pocket) oral gel; repeated every week beginning from baseline up to 4 weeks.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant decrease in PPD, GCF-ALP levels and rise in CAL 
     <break/>Antibacterial effect of TQ against against 
     <italic>P. gingivalis</italic>, 
     <italic>A. actinomycetemcomitans</italic> and 
     <italic>P. intermedia</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B62-antioxidants-09-01260" ref-type="bibr">62</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic healthy chronic periodontitis male and female patients (25–58 years) with at least 10 periodontally involved sites (≥5 mm), n = 48</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1% TQ topical (intra-pocket) oral gel; immediately after accomplishment of SRP. The gel was applied again after 48 h and the gel applied sites were covered with a periodontal pack for 7 days. Results were recorded at baseline and at weeks 4 and 12 after treatment.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant improvement in PI, GI, PPD, CAL 
     <break/>Significant improvement in the levels of IL-1β and TAOC
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B63-antioxidants-09-01260" ref-type="bibr">63</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic healthy chronic periodontitis male patients (35–56 years) with at least 4 periodontally involved sites (≥5 mm), n = 12</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biodegradable chitosan subgingival periodontal chip with integrated 0.25 mg TQ with second chip insertion at day 14. Results were recorded at day 14 and 60 of the trial.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant gains in CAL</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B65-antioxidants-09-01260" ref-type="bibr">65</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Animal</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male Wistar rats with ligature-induced periodontal inflammation (300 ± 10 g), n = 8</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic intragastric (10 mg/kg, daily for 11 days)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant reduction of alveolar bone loss and inflammatory cell infiltration 
     <break/>Maintenance of osteoblastic activity
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B66-antioxidants-09-01260" ref-type="bibr">66</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Animal</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male Fisher rats (21 days old), n = 16</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2% TQ topical oral gel and systemic administration in drinking water. The oral gel was applied daily over gingiva and the drinking water was changed 3 times a week. Outcomes were measured at day 1, 7 and 35.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant reduction in BOP, PI in rats that received TQ as oral gel or systemically 
     <break/>Less evident signs of gingivitis and periodontitis histologically in TQ treated rats 
     <break/>Antibacterial effect of TQ against subgingival bacteria
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B64-antioxidants-09-01260" ref-type="bibr">64</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial strains of 
     <italic>Fusobacterium nucleatum</italic> ATCC25586 (FN), 
     <italic>Actinomyces naeslundii</italic> X600 (AN) and 
     <italic>Streptococcus mitis</italic> ATCC 903 (
     <italic>SM</italic>)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1%, 0.01% and 0.05% TQ reagents were added to bacterial formed biofilms and incubated for 24 h and for 30 min</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibitory effect of 0.1% TQ on 
     <italic>FN</italic>-containing biofilm 
     <break/>Significantly decreased biofilm formation of 
     <italic>FN</italic> pretreated with 0.01% TQ 
     <break/>Significant cleansing effect of 0.01% and 0.05% TQ on 
     <italic>FN</italic>-containing biofilm
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B67-antioxidants-09-01260" ref-type="bibr">67</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TQ</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacterial strains of 
     <italic>Fusobacterium nucleatum</italic> ATCC 25586 (FN) and 
     <italic>Porphyromonas gingivalis</italic> A7436 (PG)
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10% TQ reagent was added to bacterial formed biofilms and incubated for 48 h</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The minimum inhibitory concentration (MIC) of TQ was 12.5 and 1.56 μg/mL in FN and PG, respectively. 
     <break/>Sub-MIC concentrations of TQ prevented biofilm formation, hemolysis activities and H2S generation of 
     <italic>FN</italic> and 
     <italic>PG</italic> and 
     <break/>TQ disintegrated bacterial membranes and reduced the expression of virulence factors in 
     <italic>FN</italic> and 
     <italic>PG</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B68-antioxidants-09-01260" ref-type="bibr">68</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <italic>NS</italic>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Twelve gram-positive and eleven Gram-negative bacterial strains, including 
     <italic>Staphylococcus aureus</italic>, 
     <italic>Enterococcus faecalis, Staphylococcus epidermidis</italic>, 
     <italic>Porphyromonas</italic> sp., 
     <italic>Proteus</italic> sp., 
     <italic>Streptococcus pneumoniae</italic>, 
     <italic>Klebsiella pneumoniae</italic>, 
     <italic>Acinetobacter baumannii/calcoaceticus</italic> and 
     <italic>Veillonella</italic> sp., isolated from supra- and subgingival plaque of periodontal patients
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methanol and essential oil solutions of 
     <italic>NS</italic> 2% ±0.35 dry extract were added to the isolated bacteria in microdilution test and Agar well diffusion assay
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibacterial effect of the essential oil and less efficiency of the methanol against all tested bacteria</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B69-antioxidants-09-01260" ref-type="bibr">69</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>PPD: Probing pocket depth; GCF-ALP: Gingival crevicular fluid alkaline phosphatase; CAL: Clinical attachment level; SRP: Scaling and root planning; PI: Plaque index; GI: Gingival index; TAOC: Total antioxidant capacity; FN: Fusobacterium nucleatum; AN: Actinomyces naeslundii; PG: Porphyromonas gingivalis.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
